Medannex
- Biotech or pharma, therapeutic R&D
Clinical-stage UK biopharma with a first-in-class annexin-A1 targeting antibody therapy.
First-in-human oncology study demonstrating impressive disease control with minimal toxicity.
Seeking investment to support ongoing oncology studies and accelerate development in additional disease indications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}